Radiopharm Theranostics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Operating Revenue	1.68	0.3	0.29	-	-
Other Revenue	-1.35	1.66	5.92	-	-
Revenue	0.33	1.96	6.21	-	-
Revenue Growth (YoY)	-94.50%	-68.46%	-	-	-
Cost of Revenue	21.72	21.61	19.53	7.49	-
Gross Profit	-21.38	-19.65	-13.32	-7.49	-
Selling, General & Admin	12.84	13.04	12.23	7.64	0.3
Operating Expenses	14.68	15.68	15.27	12.44	1.16
Operating Income	-36.07	-35.33	-28.59	-19.93	-1.16
Interest Expense	-0.61	-0.64	-0.09	-9.35	-
Interest & Investment Income	0.05	0.05	0.15	0.01	-
Currency Exchange Gain (Loss)	0.69	0.09	-0.26	-1.11	-0
EBT Excluding Unusual Items	-35.94	-35.83	-28.79	-30.38	-1.16
Gain (Loss) on Sale of Assets	-1.69	-1.69	-	-	-
Asset Writedown	-1.48	-1.48	-3.1	-	-
Other Unusual Items	-3.56	-8.86	-2.68	-	-
Pretax Income	-42.67	-47.85	-34.57	-30.38	-1.16
Income Tax Expense	0.17	0.1	0.04	0.04	-
Net Income	-43	-47.95	-34.61	-30.42	-1.16
Net Income to Common	-43	-47.95	-34.61	-30.42	-1.16
Shares Outstanding (Basic)	1,140	386	306	181	-
Shares Outstanding (Diluted)	1,140	386	306	181	-
Shares Change (YoY)	243.78%	26.36%	68.74%	-	-
EPS (Basic)	-0.04	-0.12	-0.11	-0.17	-
EPS (Diluted)	-0.04	-0.12	-0.11	-0.17	-
Free Cash Flow	-33.42	-22.98	-23.25	-9.91	-0.08
Free Cash Flow Per Share	-0.03	-0.06	-0.08	-0.06	-
Gross Margin	-	-	-214.52%	-	-
Operating Margin	-10908.64%	-1803.82%	-460.41%	-	-
Profit Margin	-13006.38%	-2448.23%	-557.36%	-	-
Free Cash Flow Margin	-10107.88%	-1173.12%	-374.36%	-	-
EBITDA	-32.99	-32.2	-25.29	-16.94	-
D&A For EBITDA	3.07	3.13	3.3	2.98	-
EBIT	-36.07	-35.33	-28.59	-19.93	-1.16

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q